Gyros AB Appoints Dr Henrik Björkman as CTO and VP Technical Affairs
News Jan 21, 2013
As part of his new role at Gyros, Henrik will have responsibility for driving strategic and operational decisions, managing product development, intellectual property, manufacturing, QA, and QC, and will oversee the existing product range. As part of the executive management team Henrik will work closely with marketing and sales departments, reporting to the board of directors.
Henrik joins Gyros from GE Healthcare Life Sciences, where he was most recently Director, MicroCal R&D, leading the MicroCal operation in Northampton, MA. He has many years of experience in senior positions within R&D, technical and management roles, at a range of life science companies from small organizations to larger, industrial enterprises. Henrik holds a PhD in Materials Science and Micro Engineering from Uppsala University.
“The technology developed at Gyros offers an exciting step forward for the biopharmaceutical community,” said Henrik. “I am excited to have the opportunity to support the continued success of the Gyros immunoassay platform.”
Erik Walldén, CEO at Gyros, commented: “We welcome Henrik to Gyros, and look forward to working with him. Bringing extensive experience in product development and manufacturing for globalized, commercial organizations in the life science tools industry, Henrik will be a great asset for the continued development of our microfluidic immunoassay technology.”
Easily Automate PK Assays for Human IgG Drugs in Preclinical SpeciesNews
At AAPS NBC event, Lumigen produced a poster summarizing the use of their pipetting robot, Andrew which can measure IgG drug concentration in a pre-clinical setting.READ MORE
Ingestible Drug-Delivery Materials May Improve Patient Treatment ComplianceNews
Hydrogel-based capsules could expand and reside in the GI tract for days, slowly releasing medication.READ MORE
Nanoparticle Delivery of Curcumin Induces Tumor Cell DeathNews
Attaching curcumin, a component of the common spice turmeric, to nanoparticles can be used to target and destroy treatment-resistant neuroblastoma tumor cellsREAD MORE